Prima secures $10m and institutional support
27 October, 2004 by Melissa TrudingerPrima Biomed (ASX: PRR) announced today it had finalised its $10 million placement to institutional and sophisticated investors.
Qld team hits new target in fat research
27 October, 2004 by Graeme O'NeillA research team at the University of Queensland has identified a promising new target for an anti-obesity therapy: an enzyme that appears to have a central role in the development of fat-storage cells called adipocytes.
Onyx falls behind in cancer drug race
26 October, 2004 by Staff WritersOnyx Pharmaceuticals - which is developing one of the most promising new cancer therapies on the horizon - has said it will not file for US approval of its kidney cancer drug as soon as some investors had anticipated.
Prima finalising $10m capital raising
25 October, 2004 by Melissa TrudingerPrima Biomed (ASX: PRR) has called a trading halt as it finalises a $10 million capital raising to institutional and sophisticated investors.
FDA approves wrinkle filler
19 October, 2004 by Staff WritersThe FDA has approved a new injectable gel, made by Genzyme and marketed by Inamed, that can be used to temporarily fill the deepest facial wrinkles.
In brief: Prana, ES Cell, Phosphagenics
14 October, 2004 by Melissa TrudingerAlzheimer's specialist Prana Biotechnology (ASX:PRR) has released data from an extension study of its Phase II PBT-1 (clioquinol) trial, showing that the drug appeared to slow the rate of decline.
Avexa forms new research partnerships
13 October, 2004 by Renate KrelleNear enough isn't good enough when it comes to structure-based drug design and medicinal chemistry. That's the reasoning behind Avexa's (ASX:AVX) new collaborations with Melbourne's St Vincent's Institute of Medical Research and the Shanghai Institute of Organic Chemistry, according to CEO Julian Chick.
AustCancer attracts $2m investment
08 October, 2004 by Melissa TrudingerUS biotech company Bioaccelerate will invest AUD$1.88 million into Australian Cancer Technologies (AustCancer, ASX:ACU) through a private share placement of 4,893,301 ACU shares at $0.384 per share.
Antisense to establish ADR program
07 October, 2004 by Melissa TrudingerAntisense Therapeutics (ASX: ANP) announced this week it would establish a level 1 American Depository Receipts (ADR) program in the US through the Bank of New York.
Prima sets sights on $10m capital raising
07 October, 2004 by Renate KrelleMelbourne's Prima Biomed (ASX:PRR) is aiming to raise between $5 and $10 million over the next two weeks to fund its research programs - particularly its Panvax vaccine technology.
Cross-linked beta-amyloid implicated in Alzheimers
06 October, 2004 by Melissa TrudingerCross-linked oligomers of beta-amyloid (AB) may be the primary neurotoxic agent in Alzheimer's disease according to Rob Moir, an expatriate Australian researcher in Rudolph Tanzi's Genetics and Aging Research Unit at Massachusetts General Hospital and Harvard University.
Acrux completes Phase I trial of testosterone lotion
06 October, 2004 by Melissa TrudingerAcrux (ASX: ACR) has completed a Phase I clinical trial of its testosterone metered-dose lotion for the treatment of hypogonadism, or low testosterone, in men.
Psiron to raise $10.5m to buy licence, boost R&D
06 October, 2004 by Renate KrelleWith plans for its anti-cancer virus therapy mapped out, Psiron (ASX:PSX) today lodged a prospectus for a non-renounceable rights issue to raise approximately $10.5 million at $0.20 a share.
Pfizer says no safety concerns in Celebrex studies
05 October, 2004 by Staff WritersThree long-term studies conducted by Pfizer seeking additional uses for its popular arthritis drug Celebrex have turned up no cardiovascular safety concerns, according to the company
Peplin trading halted
05 October, 2004 by Melissa TrudingerBrisbane based Peplin Biotech (ASX:PEP) has called a halt to trading shares on the ASX for at least a week, telling shareholders to expect a major announcement.
